P520
The metabolic modulator trimetazidine inhibits AF-induced atrial structural remodelling

Cardiovascular Research

23 April 2018

Organised by:

Read full article

Contributors

D Opacic

D Opacic

Author

A Weseler

A Weseler

Author

P Schoenleitner

P Schoenleitner

Author

A Van Hunnik

A Van Hunnik

Author

M Kuiper

M Kuiper

Author

I Akomianakis

I Akomianakis

Author

P Pasdois

P Pasdois

Author

C Antoniades

C Antoniades

Author

U Schotten

U Schotten

Author

S Verheule

S Verheule

Author

You may be interested in

Congress Presentation

Effects of trimetazidine on cardiac remodeling and premature ventricular contractions in patients with heart failure and preserved ejection fraction

29 June 2021

Congress Presentation

Left atrial glucose metabolism by 18F-FDG PET/CT in persistent atrial fibrillation and after return to sinus rhythm

27 August 2023

Congress Presentation

Impact on atrial remodeling of dapagliflozin in patients with heart failure: MODA study. rational and design.

20 May 2023

Congress Session

Young Investigator Award Basic and Translational Science

1 April 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources